$43.53 +0.15 (0.34%)
MRBL Enhanced Equity ETF (EDGE)
Company News
PDSB Loss Improves as Costs Drop
PDS Biotechnology reported a Q2 2025 net loss of $0.21 per share, beating analyst expectations. The company continues advancing its immunotherapy platforms in oncology and infectious disease, with notable progress in clinical trials for HPV and colorectal cancer treatments.